AstraZeneca’s blockbuster BTK inhibitor Calquence significantly improved progression-free survival when used as a frontline ...

Boehringer Ingelheim on Wednesday won the FDA’s approval for a high-concentration and citrate-free version of its Humira ...

In a bid to improve competition in the industry, the U.S. Federal Trade Commission is challenging the patents of 20 different ...

Astellas Pharma and Poseida Therapeutics have entered into a second CAR-T contract to develop novel and flexible allogeneic ...

The new company, BridgeBio Oncology Therapeutics, is looking to advance two KRAS inhibitors and a blocker of the interaction ...

Ahead of the FDA’s June target action date for Sarepta’s Duchenne muscular dystrophy gene therapy, ICER Chief Medical Officer David Rind blasted the regulator’s accelerated pathway in a JAMA viewpoint ...

Based on strong overall and progression-free survival data in its Phase III confirmatory study, Pfizer and Genmab’s ...

It wasn’t calls from lawmakers but market competition with Eli Lilly’s Zepbound that prompted Novo Nordisk to lower the prices of its blockbuster weight-loss drug.

It’s important to quit your job the right way so you can exit on a positive note, which could benefit you in the future.

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu significantly improved progression-free survival in ...

Citing a strategic prioritization by Moderna, Metagenomi announced Wednesday that the partners have “mutually agreed” to ...

Follow News Editor Greg Slabodkin and Managing Editor Jef Akst as they travel with some 8,000 others for discussions of cell and gene therapy advances, challenges, regulations and more.